GlassScriptPhysician profile
Leandra S Armstead
NPI 1871064816
$4,134.70
in general payments reported to CMS, 2019-2025
15 companies · $376 in 2025
The $376 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $539 · 2022: $1,066 · 2023: $1,812 · 2024: $341 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,712 · Travel and Lodging: $818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,711.66 |
| Travel and Lodging | $817.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,961.76 | 2021-2025 | |
| Ipsen Innovation | $1,112.81 | 2023 | Dysport |
| Lilly USA, LLC | $253.78 | 2022-2024 | Emgality, Reyvow |
| Lundbeck LLC | $185.30 | 2023-2024 | Vyepti |
| Pfizer INC. | $159.40 | 2023-2025 | |
| Allergan, INC. | $147.47 | 2022 | |
| Amgen INC. | $81.55 | 2022 | |
| Avanir Pharmaceuticals, INC. | $56.68 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.51 | 2022 | |
| Corium, LLC | $32.62 | 2023 | Adlarity |
| Takeda Pharmaceuticals U.S.A., INC. | $27.85 | 2022 | |
| Impel Pharmaceuticals INC. | $23.99 | 2023 | Trudhesa |
| Teva Pharmaceuticals USA, INC. | $19.48 | 2022 | |
| Eisai INC. | $16.47 | 2022 | |
| Glaxosmithkline, LLC. | $12.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leandra Armstead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.